Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a clinical research study designed to evaluate whether a conditioning regimen
consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine
supported by donor blood cells will result in rapid recovery and a high rate of long-lasting
remissions in patients with leukemia, lymphoma and myeloma.